📊 PTGX Key Takeaways
Is Protagonist Therapeutics, Inc (PTGX) a Good Investment?
Protagonist Therapeutics exhibits severe operational distress with catastrophic 89% YoY revenue collapse and $158M operating losses, indicating major clinical or commercial setbacks. While the balance sheet provides temporary protection with $128M cash and minimal debt, the company's inability to control costs relative to revenue reflects fundamental business viability concerns requiring urgent clinical or strategic resolution.
Why Buy Protagonist Therapeutics, Inc Stock? PTGX Key Strengths
- Strong balance sheet with $128.4M cash and only $9.8M long-term debt
- Exceptional liquidity position (12.71x current ratio) provides extended operational runway
- Positive free cash flow of $56.1M despite operating losses suggests non-cash charges or milestone payments offset burn
PTGX Stock Risks: Protagonist Therapeutics, Inc Investment Risks
- Catastrophic 89.4% YoY revenue collapse indicates major product failure, trial setback, or partnership loss
- Operating margin of -343.6% reflects severe cost structure misalignment with revenue base - unsustainable model
- Burn rate at $158M operating loss against $46M revenue shows path to insolvency unless revenue recovers or costs drastically cut
Key Metrics to Watch
- Revenue stabilization and growth trajectory - assess if decline bottoms or continues deteriorating
- Operating expense structure and reduction initiatives - critical to determine viability of cost correction
- Cash burn rate and months of runway remaining - determine time window for operational turnaround
Protagonist Therapeutics, Inc (PTGX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 121.9% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 12.71x current ratio provides a solid financial cushion.
PTGX Profit Margin, ROE & Profitability Analysis
PTGX vs Healthcare Sector: How Protagonist Therapeutics, Inc Compares
How Protagonist Therapeutics, Inc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Protagonist Therapeutics, Inc Stock Overvalued? PTGX Valuation Analysis 2026
Based on fundamental analysis, Protagonist Therapeutics, Inc has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Protagonist Therapeutics, Inc Balance Sheet: PTGX Debt, Cash & Liquidity
PTGX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Protagonist Therapeutics, Inc's revenue has grown significantly by 1,418% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.39 indicates the company is currently unprofitable.
PTGX Revenue Growth, EPS Growth & YoY Performance
PTGX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $4.7M | -$33.2M | $-0.54 |
| Q2 2025 | $4.2M | -$30.6M | $-0.50 |
| Q1 2025 | $28.3M | -$11.7M | $-0.19 |
| Q3 2024 | N/A | -$33.2M | $-0.54 |
| Q2 2024 | N/A | -$30.6M | $-0.50 |
| Q1 2024 | N/A | -$33.7M | $-0.67 |
| Q3 2023 | N/A | -$31.2M | $-0.58 |
| Q2 2023 | N/A | -$38.5M | $-0.68 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Protagonist Therapeutics, Inc Dividends, Buybacks & Capital Allocation
PTGX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Protagonist Therapeutics, Inc (CIK: 0001377121)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PTGX
What is the AI rating for PTGX?
Protagonist Therapeutics, Inc (PTGX) has an AI rating of SELL with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PTGX's key strengths?
Claude: Strong balance sheet with $128.4M cash and only $9.8M long-term debt. Exceptional liquidity position (12.71x current ratio) provides extended operational runway.
What are the risks of investing in PTGX?
Claude: Catastrophic 89.4% YoY revenue collapse indicates major product failure, trial setback, or partnership loss. Operating margin of -343.6% reflects severe cost structure misalignment with revenue base - unsustainable model.
What is PTGX's revenue and growth?
Protagonist Therapeutics, Inc reported revenue of $46.0M.
Does PTGX pay dividends?
Protagonist Therapeutics, Inc does not currently pay dividends.
Where can I find PTGX SEC filings?
Official SEC filings for Protagonist Therapeutics, Inc (CIK: 0001377121) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PTGX's EPS?
Protagonist Therapeutics, Inc has a diluted EPS of $-2.05.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PTGX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Protagonist Therapeutics, Inc has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is PTGX stock overvalued or undervalued?
Valuation metrics for PTGX: ROE of -21.2% (sector avg: 15%), net margin of -282.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy PTGX stock in 2026?
Our dual AI analysis gives Protagonist Therapeutics, Inc a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PTGX's free cash flow?
Protagonist Therapeutics, Inc's operating cash flow is $57.7M, with capital expenditures of $1.6M. FCF margin is 121.9%.
How does PTGX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -282.8% (avg: 12%), ROE -21.2% (avg: 15%), current ratio 12.71 (avg: 2).